Breakthrough in Multiple Sclerosis Experimental Treatment: Promising Results from New Anti-CD40L Monoclonal Antibody

Novel Experimental Therapy Shows High Efficacy in MS Management Without Increased Infection Risk

Topline:

A new study reveals that a second-generation anti-CD40L monoclonal antibody significantly reduces disease activity in multiple sclerosis (MS) patients, offering hope for improved treatment without added infection risk.